AtriCure
AtriCure's revenue rose 14.9% to $534 million in fiscal 2025. Its operating margin was −1.8%, up from −8.6% a year earlier. Free cash flow was $48 million, up 6381.1%. The diluted share count rose 1.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What AtriCure does
AtriCure makes devices that surgeons use to treat atrial fibrillation (Afib), an irregular heartbeat, to manage the left atrial appendage (a small pouch in the heart where blood clots can form), and to ease pain after surgery.
Its ablation and left atrial appendage products are used during open-heart surgery for another condition, such as a valve repair or bypass, and in stand-alone minimally invasive procedures, sometimes combined with catheter ablation by a heart-rhythm specialist. Its pain products, including cryoICE cryoSPHERE and cryoXT probes, freeze nerves during heart, chest or amputation surgery to give temporary pain relief while the nerves regrow.
AtriCure sells to medical centers through its own sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia and Canada, and through distributors in other countries. Its business is mainly transacted in U.S. dollars. Its manufacturing is highly concentrated, and it relies on single or limited suppliers for some parts.
Its biggest risks, as it describes them
- Its products may not win wide acceptance in the United States.
- Competing products and procedures may take market share.
- Clinical data may not be positive or meet FDA requirements.
- Its reliance on independent distributors outside the U.S. and on single or limited-source suppliers.
- Its manufacturing is concentrated, so a disruption at its facilities could hurt sales.
Income statement
AtriCure lost money in fiscal 2025: a net loss of $11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 119 | 121 | 137 | 123 | 167 |
| Debt incl. finance leases | 71 | 70 | 63 | 65 | 69 |
| Net debt (negative means net cash) | −48 | −51 | −74 | −58 | −98 |
| Net debt to EBITDA | −0.7x | — | — | — | −8.9x |
| Debt to equity | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x |
| Interest coverage | 11.2x | −8.6x | −3.9x | −6.2x | −1.6x |
| Current ratio | 3.5x | 3.7x | 3.6x | 3.6x | 4.0x |
| Quick ratio | 2.8x | 2.9x | 2.7x | 2.6x | 3.0x |
Cash flow
Projections
Project AtriCure's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What AtriCure says to expect
- Full year 2026: revenue and adjusted EBITDA
Full year 2026 revenue is now projected to be approximately $606 million to $610 million, and management also projects full year 2026 adjusted EBITDA of approximately $91 million to $94 million.
- Full year 2026: earnings per share
Full year 2026 net income per share is expected to be in the range of $0.21 to $0.27 and adjusted earnings per share of approximately $0.40 to $0.46.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought AtriCure shares on the open market, and 8 insiders sold $4.4 million, $879,833 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Salvatore PriviteraChief Technical Officer | Sold plan | 4,519 | $60.00 | $271,140 | Form 4 |
| Sep 11, 2026 | Regina E GrovesDirector | Sold | 5,313 | $54.22 | $288,071 | Form 4 |
| Sep 8, 2026 | Salvatore PriviteraChief Technical Officer | Sold plan | 3,657 | $55.00 | $201,135 | Form 4 |
| Sep 2, 2026 | Salvatore PriviteraChief Technical Officer | Sold plan | 7,763 | $52.50 | $407,558 | Form 4 |
| Aug 24, 2026 | Karl S. DahlquistChief Legal Officer | Sold | 9,370 | $48.89 | $458,099 | Form 4 |
| Aug 5, 2026 | Karen PrangeDirector | Sold | 3,564 | $38.80 | $138,283 | Form 4 |
| Aug 5, 2026 | Maggie YuenDirector | Sold | 3,500 | $38.42 | $134,470 | Form 4 |
| Jul 29, 2026 | Justin J NozneskyChief Mktg & Strategy Officer | Sold | 6,182 | $38.80 | $239,862 | Form 4 |
| Jul 28, 2026 | Sven WehrweinDirector | Sold | 25,000 | $37.84 | $946,000 | Form 4 |
| Jul 28, 2026 | Vinayak DoraiswamyChief Scientific Officer | Sold | 6,000 | $38.88 | $233,280 | Form 4 |
| May 20, 2026 | Karen PrangeDirector | Sold | 3,000 | $28.65 | $85,950 | Form 4 |
| May 15, 2026 | Vinayak DoraiswamyChief Scientific Officer | Sold | 5,000 | $28.13 | $140,650 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 9 | 7 of 9 |
| Rule of 40 | 19.0% | 16.7% | 23.9% |
| Altman Z'' | 3.17 | 2.76 | 3.44 |
| Accruals ratio | −5.8% | −9.3% | −10.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 4 of 9 | 7 of 9 |
Compare
Put AtriCure side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AtriCure | FY25 | 14.9% | −1.8% | 9.0% | −1.9% | −8.9x | 7 | |
| Glaukos | FY25 | 32.3% | −39.3% | −4.4% | — | — | — | Compare |
| Bioventus | FY25 | −0.9% | 9.5% | 12.7% | 11.1% | 2.5x | 8 | Compare |
| UFP Technologies | FY25 | 19.5% | 15.3% | — | 14.4% | 1.0x | 5 | Compare |
| TransMedics Group | FY25 | 37.1% | 17.9% | 22.1% | 27.5% | −0.2x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 155 | 175 | 202 | 231 | 206 | 274 | 330 | 399 | 465 | 534 |
| Revenue growth | 19.5% | 12.6% | 15.4% | 14.5% | −10.5% | 32.8% | 20.4% | 20.8% | 16.6% | 14.9% |
| Gross profit | 111 | 126 | 147 | 170 | 149 | 206 | 246 | 300 | 348 | 401 |
| Research and development | 36 | 34 | 35 | 41 | 43 | 48 | 57 | 74 | 96 | 99 |
| Operating income | −31 | −25 | −17 | −33 | −44 | 55 | −43 | −27 | −40 | −9 |
| Net income | −33 | −27 | −21 | −35 | −48 | 50 | −46 | −30 | −45 | −11 |
| Diluted EPS (US$) | −1.05 | −0.83 | −0.62 | −0.94 | −1.14 | 1.09 | −1.02 | −0.66 | −0.95 | −0.24 |
| Diluted shares (millions) | 32 | 32 | 34 | 38 | 42 | 46 | 46 | 46 | 47 | 48 |
| Cash flow | ||||||||||
| Cash from operations | −15 | −9 | −4 | −16 | −20 | −14 | −22 | 4 | 12 | 57 |
| Capital expenditure | 8 | 6 | 6 | 12 | 5 | 10 | 17 | 12 | 12 | 9 |
| Free cash flow | −23 | −15 | −10 | −28 | −25 | −24 | −39 | −8 | 1 | 48 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 12 | 15 | 16 | 18 | 23 | 28 | 29 | 36 | 40 | 45 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 44 | 34 | 124 | 82 | 244 | 119 | 121 | 137 | 123 | 167 |
| Debt incl. finance leases | 39 | 37 | 53 | 72 | 72 | 71 | 70 | 63 | 65 | 69 |
| Total assets | 276 | 268 | 357 | 558 | 714 | 615 | 585 | 614 | 609 | 654 |
| Total liabilities | 108 | 106 | 107 | 310 | 302 | 132 | 129 | 148 | 148 | 162 |
| Shareholders' equity | 168 | 161 | 249 | 247 | 412 | 484 | 457 | 466 | 461 | 492 |
| Margins and ratios | ||||||||||
| Gross margin | 71.6% | 72.2% | 73.0% | 73.8% | 72.3% | 75.0% | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating margin | −20.1% | −14.3% | −8.5% | −14.3% | −21.4% | 20.1% | −12.9% | −6.7% | −8.6% | −1.8% |
| Net margin | −21.5% | −15.4% | −10.5% | −15.2% | −23.3% | 18.3% | −14.1% | −7.6% | −9.6% | −2.1% |
| Free cash flow margin | −14.7% | −8.8% | −5.2% | −12.1% | −12.2% | −8.6% | −11.8% | −1.9% | 0.2% | 9.0% |
| Rule of 40 (growth + FCF margin) | 4.8% | 3.9% | 10.3% | 2.3% | −22.7% | 24.2% | 8.6% | 19.0% | 16.7% | 23.9% |
| Return on capital | — | −12.1% | −7.9% | −12.6% | −14.6% | 16.3% | −8.0% | −5.3% | −8.0% | −1.9% |
| Return on equity | −18.8% | −16.3% | −10.3% | −14.2% | −14.6% | 11.2% | −9.9% | −6.6% | −9.6% | −2.4% |
| Return on assets | −12.1% | −9.9% | −6.8% | −7.7% | −7.6% | 7.5% | −7.7% | −5.1% | −7.3% | −1.8% |
| Net debt to EBITDA | — | — | — | — | — | −0.7x | — | — | — | −8.9x |